nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2-advanced breast cancer
Hamiton, E.; Cortes, J.; Dieras, V.; Ozyilkan, O.; Chen, S-C.; Petrakova, K.; Manikhas, A.; Jerusalem, G.; Hegg, R.; Lu, Y.; Bear, M.M.; Johnston, E.L.; Martin, M. (2019)